Marc Atzenhoefer, MD
Cardiovascular Disease · Milwaukee, WINPI 1740676956
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 88.3% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $16,330, more than ten times the $99 reported in 2019. Among cardiovascular disease clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $171.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$30K
- Heartflow, Inc.$1K
- Siemens Medical Solutions USA, Inc.$962
- Edwards Lifesciences$256
- Pfizer$168
- Amgen$160
- plus $1K from 12 others
What the payments were for
- Consulting fees$14,64443%
- Speaking & faculty fees$4,25112%
- Travel & lodging$9,09427%
- Food & beverage$6,18418%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 100 | $30,248 |
| Heartflow, Inc. | 27 | $1,232 |
| Siemens Medical Solutions USA, Inc. | 7 | $962 |
| Edwards Lifesciences | 5 | $256 |
| Pfizer | 8 | $168 |
| Amgen | 8 | $160 |
| Alnylam Pharmaceuticals Inc. | 6 | $159 |
| Novartis | 7 | $157 |
| Boston Scientific | 7 | $152 |
| Novo Nordisk | 6 | $142 |
| Boehringer Ingelheim | 1 | $125 |
| Abiomed | 1 | $100 |
| AstraZeneca | 5 | $100 |
| Astellas Pharma US Inc | 1 | $99 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Cvrx, Inc. | 3 | $67 |
| Merck | 2 | $39 |
| Bayer | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$26,430
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,508
- NAEOTOM Alpha$830
- FFRct$645
- MitraClip$154
- Edwards SAPIEN 3 Transcatheter Heart Valve$125
- JARDIANCE$125
- Impella$100
How this compares
$34,273 in reported general payments places this provider in the 90th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $133,794 |
| JardianceEmpagliflozin | 99 | $124,067 |
| EntrestoSacubitril/Valsartan | 29 | $45,740 |
| XareltoRivaroxaban | 24 | $25,241 |
| Bumetanide | 181 | $6,379 |
| Metoprolol Succinate | 185 | $3,735 |
| Atorvastatin Calcium | 202 | $2,743 |
| Rosuvastatin Calcium | 135 | $2,554 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 78 | $1,314 |
| Spironolactone | 124 | $1,291 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 17 | $843 |
| ClopidogrelClopidogrel Bisulfate | 57 | $795 |
| Losartan Potassium | 66 | $730 |
| Potassium Chloride | 14 | $662 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $168 | $133,794120 claims |
| Boehringer IngelheimJardiance | $125 | $124,06799 claims |
| NovartisEntresto | $157 | $45,74029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Milwaukee
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Prakash ShahMilwaukee$51K
- Sisir SiddamsettiMilwaukee$44K
- Manmeet SinghMilwaukee$39K
- Jordan SwisherMilwaukee$36K
- Christian BreburdaMilwaukee$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.